APSR2026-734

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP11-014
P56
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1221215-46904-APSR26_Poster Nepal FINAL_438437.pdf
Format: PDF Only
09. Asthma
5

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

S. Krishna Shrestha - Mediciti Hospital Consultant & HOD, Department of Pulmonary, Critical care and Sleep medicine Lalitpur Nepal
Aniruddha Mukhopadhyay - Cipla Ltd Global Medical Affairs Mumbai India
Jaideep Gogtay - Cipla Ltd Global Medical Affairs Mumbai India
Vaibhav Gaur * Cipla Ltd Global Medical Affairs Mumbai India
Milesh Jung Sijapati - Kist Medical College & Teaching Hospital Specialist Pulmonologist Kathmandu Nepal
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Vaibhav
Gaur
vaibhav2india@gmail.com
+919830061506
51-60
Nepal
Original Research
Clinicians’ Experience of Asthma Management: A Real-World Study from Nepal (CLEAR)
Maximum 25 words
Abstract Content
Globally, asthma affects a significant proportion of the population, including in Nepal. The study aimed to understand the current clinical experience and perspectives of clinicians in Nepal regarding asthma management.
This was a cross-sectional, questionnaire-based survey conducted among 124 experienced clinicians [physicians(90), general practitioners(19), paediatricians(8) and pulmonologists(7)] from 33 cities across Nepal.
On average, clinicians reported that 16% of their patients had asthma. 59% of patients were aged ≥12 years. They had varying asthma severity [Global Initiative for Asthma (GINA) Steps 1&2(51%), Step 3(25%), Step 4(15%), Step 5(9%)]. Most clinicians rate guidelines(63%), training(60%) and their own clinical experience(56%) as most important factors influencing their asthma management strategies. Among most clinicians, low-dose inhaled corticosteroid (ICS)/formoterol was preferred as both reliever(59%) and controller(47%) therapy in mild asthma. Most clinicians(70%) preferred prescribing ICS/formoterol in GINA Steps 3-5. Equal preference was given to metered dose inhalers(MDI) and dry powder inhalers(DPIs). Clinicians reported that 61% of asthma patients efficiently used budesonide/formoterol as Maintenance And Reliever Therapy(MART). Most clinicians reported suitability of as-needed low-dose ICS/formoterol for mild(44%), severe(41%), and adolescent asthma(38%). 50% of clinicians agreed that irrespective of age of patient, pMDI must be used with spacer. 93% agreed that right device selection improves adherence. Clinicians identified patient-friendly devices(69%), support of clinical evidence(65%) and rapid onset of action(63%) as the most important criteria for selecting ICS/LABAs. 27% of patients were hesitant to accept inhalation therapy, predominantly those in GINA Steps 1–2 (59%). Clinicians reported regular follow-up(66%) and use of patient education materials(27%) were the most applied method to ensure patient adherence to inhalation therapy.
Clinicians in Nepal largely follow guideline recommended asthma care, with widespread use of ICS/formoterol across severities. Inhaler hesitancy, particularly in mild asthma, remains a key gap, emphasizing the need for improved counseling and individualized device selection.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Asthma, MART, Nepal
maximum 3 keywords and no abbreviations, separated by commas
 
327